Home › Arena Pharmaceuticals Announces BELVIQ (lorcaserin HCl) New Drug Submission In Canada
 

Keywords :   


Arena Pharmaceuticals Announces BELVIQ (lorcaserin HCl) New Drug Submission In Canada

2013-07-03 06:56:53| drugdiscoveryonline News Articles

Arena Pharmaceuticals, Inc.announced recently that Eisai Limited (based inMississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission (NDS) for BELVIQ™ (lorcaserin HCl) with Health Canada

Tags: canada drug submission arena

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.10MCC acquires smart label solutions provider Starport Technologies
07.10UPM Raflatac announces Packaging Recyclability Guide
07.10Sun Chemical issues new sustainability report
07.10Hurricane Milton Public Advisory Number 10
07.10Hurricane Leslie Graphics
07.10Hurricane Leslie Forecast Discussion Number 21
07.10Hurricane Leslie Wind Speed Probabilities Number 21
07.10Hurricane Leslie Forecast Advisory Number 21
More »